WHITEPAPER
Simplifying the Low-GWP pMDI Transition
A propellant-dispersible tablet platform for faster reformulation, lower manufacturing risk, and a defensible IP position.
Respitab®: separating formulation from the pressure vessel
How a tablet-based platform moves pMDI development onto standard solid-dose equipment.
- 15 pages · PDF
- For formulation, CMC & programme leads
- Author: Andrew Brown, PhD, CEO
Get the Whitepaper
Fill the form below to receive access.